The CPV-2c variant has not been described in the country yet. For example, in Medellin and Bucaramanga, the CPV-2a and 2b variants were detected in 6-month-old puppies. Few epidemiological studies have been conducted in the country. Nevertheless, laboratory confirmation is rare. Since then, canine parvovirus disease has been diagnosed frequently in Colombian veterinary clinics. In Colombia, CPV-2 was reported for the first time in 1980. On the other hand, the V555 residue has been challenged because this amino acid does not present changes in the actuality variants. While CPV-2a and CPV-2b have different N426D and I555V residues of VP2, CPV-2c differs only in the N/D426E residue. In 2000, a new variant (CPV-2c) was described using molecular biology techniques in Italy. Monoclonal antibody development in 1980 allowed the recognition of 2 antigenic variants-CPV-2a and CPV-2b. Mutations at only 3 amino acids (K93N, V103A, and D323Y) on the VP2 increase infection range from felines to canines. CPV-2 shows 98% genome identity to Feline Panleukopenia Virus (FPLV) and Mink Enteritis Virus and probably evolved from the FPLV. This virus has four genes in 2 Open Reading Frames (ORFs): ORF1 encodes non-structural proteins NS1 and NS2, and ORF2 encodes capsid proteins VP1, VP2, and VP3 (cleaved from VP2 by host proteases), with a role in receptor binding and stimulation of neutralizing antibodies.

The virus is a small, non-enveloped virus with a spherical shape, icosahedral capsid, and single-stranded DNA genome of ≤ 5 kb. Canine parvovirus type 2 (CPV-2), which is classified into 3 subtypes (CPV-2a, CPV-2b, and CPV-2c), is from the Carnivore protoparvovirus 1 ( Parvoviridae, Parvovirinae, Protoparvovirus) species.

How to change master sequence bioedit